Novo Nordisk Valuation Looks Appropriate Given Uncertainties -- Market Talk

Dow Jones

Yesterday

0701 GMT - Novo Nordisk's valuation now looks broadly appropriate given both near and long-term uncertainties, Citi analysts write. Shares found a floor in the fourth quarter of 2025 after falling over 70% from the mid-2024 highs, and the stock has rebounded over 20% year-to-date. Citi sees a tough 2026 outlook given U.S. pricing, copycat drugs, semaglutide patent expiries, and a sluggish diabetes market, among other things. An impressive initial Wegovy pill launch is a potential offset, but with just two weeks data it is too early to extrapolate, the bank adds. Obesity represents a huge volume opportunity, but prices are eroding and competition creates uncertainty. The bank initiates coverage of Novo Nordisk stock with a neutral rating and 400 Danish kroner target price. Shares closed at 397.05 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

January 27, 2026 02:04 ET (07:04 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2606031242"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606031242\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606031242?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 15:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606031242","market":"nz","top_or_hot":-1,"title":"Novo Nordisk Valuation Looks Appropriate Given Uncertainties -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0701 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s valuation now looks broadly appropriate given both near and long-term uncertainties, Citi analysts write. Shares found a floor in the fourth quarter of 2025 after falling over 70% from the mid-2024 highs, and the stock has rebounded over 20% year-to-date. Citi sees a tough 2026 outlook given U.S. pricing, copycat drugs, semaglutide patent expiries, and a sluggish diabetes market, among other things. An impressive initial Wegovy pill launch is a potential offset, but with just two weeks data it is too early to extrapolate, the bank adds. Obesity represents a huge volume opportunity, but prices are eroding and competition creates uncertainty. The bank initiates coverage of Novo Nordisk stock with a neutral rating and 400 Danish kroner target price. Shares closed at 397.05 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 27, 2026 02:04 ET (07:04 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Valuation Looks Appropriate Given Uncertainties -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Valuation Looks Appropriate Given Uncertainties -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-27 15:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0701 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s valuation now looks broadly appropriate given both near and long-term uncertainties, Citi analysts write. Shares found a floor in the fourth quarter of 2025 after falling over 70% from the mid-2024 highs, and the stock has rebounded over 20% year-to-date. Citi sees a tough 2026 outlook given U.S. pricing, copycat drugs, semaglutide patent expiries, and a sluggish diabetes market, among other things. An impressive initial Wegovy pill launch is a potential offset, but with just two weeks data it is too early to extrapolate, the bank adds. Obesity represents a huge volume opportunity, but prices are eroding and competition creates uncertainty. The bank initiates coverage of Novo Nordisk stock with a neutral rating and 400 Danish kroner target price. Shares closed at 397.05 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 27, 2026 02:04 ET (07:04 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2606031242","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606031242","pubTimestamp":1769497440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0701 GMT - Novo Nordisk's valuation now looks broadly appropriate given both near and long-term uncertainties, Citi analysts write. Shares found a floor in the fourth quarter of 2025 after falling over 70% from the mid-2024 highs, and the stock has rebounded over 20% year-to-date. Citi sees a tough 2026 outlook given U.S. pricing, copycat drugs, semaglutide patent expiries, and a sluggish diabetes market, among other things. An impressive initial Wegovy pill launch is a potential offset, but with just two weeks data it is too early to extrapolate, the bank adds. Obesity represents a huge volume opportunity, but prices are eroding and competition creates uncertainty. The bank initiates coverage of Novo Nordisk stock with a neutral rating and 400 Danish kroner target price. Shares closed at 397.05 kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVO":"诺和诺德","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","BK4599":"减肥药"},"translate_title":"鉴于不确定性，诺和诺德估值看起来合适——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.95},"content_text":"0701 GMT - Novo Nordisk's valuation now looks broadly appropriate given both near and long-term uncertainties, Citi analysts write. Shares found a floor in the fourth quarter of 2025 after falling over 70% from the mid-2024 highs, and the stock has rebounded over 20% year-to-date. Citi sees a tough 2026 outlook given U.S. pricing, copycat drugs, semaglutide patent expiries, and a sluggish diabetes market, among other things. An impressive initial Wegovy pill launch is a potential offset, but with just two weeks data it is too early to extrapolate, the bank adds. Obesity represents a huge volume opportunity, but prices are eroding and competition creates uncertainty. The bank initiates coverage of Novo Nordisk stock with a neutral rating and 400 Danish kroner target price. Shares closed at 397.05 kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 27, 2026 02:04 ET (07:04 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}